Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02798289 · ClinicalTrials.gov registry record · NA
Acute Tear Production Following Single Use of the Oculeve Intranasal Neurostimulator
A NA study of Dry Eye Syndrome and Keratoconjunctivitis Sicca, sponsored by Oculeve.
- Completed
- Registry status
- NA
- Development phase
- 55
- Enrollment target
- 2
- Study locations
NCT02798289: Completed NA study of Dry Eye Syndrome and Keratoconjunctivitis Sicca, sponsored by Oculeve.
NCT02798289 is a NA study of Dry Eye Syndrome and Keratoconjunctivitis Sicca that has completed, run by Oculeve. The registered enrollment target is 55 participants, below the 159-participant average among 10 other Dry Eye Syndrome trials with a reported enrollment target (65% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02798289, a NA study of Dry Eye Syndrome and Keratoconjunctivitis Sicca, has completed, sponsored by Oculeve.
- COMPLETED
- Registry status
- NA
- Development phase
- 55 participants
- Enrollment target
- 2
- Study locations
Study Summary
The primary objective of this study is to evaluate acute tear production as measured by tear meniscus height (TMH) captured by optical coherence tomography (OCT) after single use of the Oculeve Intranasal Neurostimulator (OIN) in participants with dry eye.
Primary Outcome
Tear meniscus Height was measured before and after stimulation with Oculeve Intranasal Neurostimulator using Optical Coherence Tomography.
Conditions Studied
Interventions
- DEVICE Oculeve Intranasal Neurostimulator
Study Locations (2)
California
- Sall Research Medical Center - Artesia
- Aesthetic Eyecare Institute - Newport Beach
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2016-06 |
| Est. Completion | 2016-08 |
| Phase | NA |
What the finished NCT02798289 record still lists
NCT02798289 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 55 participants, a relatively small participant target, below the 159-participant average among 10 other Dry Eye Syndrome trials with a reported enrollment target (65% lower).
The record links to 2 conditions, with Dry Eye Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Oculeve Intranasal Neurostimulator is the first listed.
NCT02798289 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT02798289 about?
NCT02798289 is a clinical study titled "Acute Tear Production Following Single Use of the Oculeve Intranasal Neurostimulator". The primary objective of this study is to evaluate acute tear production as measured by tear meniscus height (TMH) captured by optical coherence tomography (OCT) after single use of the Oculeve Intranasal Neurostimulator (OIN) in participants with dry eye.
What is the current status of trial NCT02798289?
This trial is currently completed. It is a NA study. The enrollment target is 55 participants. The study started on 2016-06. Estimated completion is 2016-08.
What conditions does trial NCT02798289 study?
This clinical trial studies the following conditions: Dry Eye Syndrome, Keratoconjunctivitis Sicca.
What interventions are being tested in trial NCT02798289?
The interventions under investigation include: Oculeve Intranasal Neurostimulator (DEVICE).
Who is sponsoring clinical trial NCT02798289?
This trial is sponsored by Oculeve, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02798289 being conducted?
This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dry Eye Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02798289's enrollment target sits among peer trials
55 6th of 10 higher than 5 of 10 other Dry Eye Syndrome trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Dry Eye Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Oral Omega-3 Fatty Acids in the Treatment of Dry Eye Syndrome
COMPLETED · NA
-
The Effect of a New Emulsion in Dry Eye Patients on Tear Layer Aberrometry, Contrast Sensitivity, and Reading Ability
COMPLETED · NA
-
A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants With Systemic Lupus Erythematosus (SLE) and Sjogren's Disease (SjD)
RECRUITING · Phase 1
-
Study of SkQ1 as Treatment for Dry-eye Syndrome
COMPLETED · Phase 3
-
Safety and Efficacy Study of Iontophoresis and Dexamethasone Phosphate to Treat Dry Eye
COMPLETED · Phase 2
-
Safety, PK and Efficacy Study of SJP-0132 in Subjects With Dry Eye Disease
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01638676 · 55 participants · Phase 1
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
- NCT01906385 · 55 participants · Phase 1
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- NCT03007030 · 55 participants · Phase 2
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
- NCT03152058 · 55 participants · Phase 2
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia